Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older

Won Suk Choi, Jung Hyun Choi, Dong Sik Jung, Hee Jung Choi, Yeon Sook Kim, Jacob Lee, Hee Chang Jang, Eui Cheol Shin, Jun Sik Park, Hun Kim, Hee Jin Cheong

Research output: Contribution to journalArticlepeer-review

5 Scopus citations


A multi-centre, randomised, double-blinded, active-controlled, parallel-group clinical trial was carried out to assess the immunogenicity and safety of NBP608—a newly developed live-attenuated zoster vaccine in Korea—relative to Zostavax® in healthy adults aged 50 years or older. Immune responses to the vaccine were evaluated by glycoprotein enzyme-linked immunosorbent assay (gpELISA) and enzyme-linked immunosorbent spot (ELISPOT) assays using the interferon (IFN)-γ and interleukin (IL)-2 FluoroSpot kit 6 weeks after vaccination. Safety was monitored for 26 weeks based on subjects’ diaries, spontaneous reports from subjects, and history taking by the investigators. A total of 845 subjects participated in the screening, and 823 received the vaccination (413 in the NBP608 group and 411 in the comparator group). The gpELISA-determined geometric mean fold rise from baseline to post NBP608 vaccination was 2.75 [95% confidence interval, CI (2.57, 2.94)]. The gpELISA-determined adjusted geometric mean titers (GMTs) of NBP608 and the comparator were 1346.37 [95% CI (1273.99, 1422.87)] and 1674.94 [95% CI (1585.35, 1769.58)], respectively. The adjusted GMT ratio of NBP608 to the comparator was 0.80 [95% CI (0.75, 0.87)]. There was no statistically significant difference between two groups in terms of the geometric mean spot numbers determined by IFN-γ and IL-2 ELISPOT assays at 6 weeks post vaccination (P = 0.7232, 0.3844). The incidence of adverse events (AEs) within 6 weeks post vaccination was 49.82% overall (410/823, 941 cases), 50.73% (209/412, 474 cases) in the NBP608 group, and 48.91% (201/411, 467 cases) in the comparator group. The difference in AE rate between the two groups was not statistically significant (P = 0.6010). Most AEs were mild, with a rate of 83.12% in the NBP608 group and 75.37% in the comparator group. Thus, NBP608 is non-inferior to Zostavax® in terms of inducing the immune response and can be safely administered to adults aged 50 years or older. Identifier: NCT03120364.

Original languageEnglish
Pages (from-to)3605-3610
Number of pages6
Issue number27
StatePublished - 12 Jun 2019

Bibliographical note

Funding Information:
This study was supported by SK bioscience Co., Ltd. The study was designed, executed, and analysed by the sponsor. Although the sponsor reviewed a draft of the manuscript, the opinions expressed in this article do not necessarily reflect those of the sponsor.

Publisher Copyright:
© 2019


  • Attenuated vaccine
  • Clinical trial
  • Herpes zoster vaccine
  • Immunogenicity
  • Prevention of herpes zoster
  • Safety


Dive into the research topics of 'Immunogenicity and safety of a new live attenuated herpes zoster vaccine (NBP608) compared to Zostavax® in healthy adults aged 50 years and older'. Together they form a unique fingerprint.

Cite this